Table 3 CD47 antagonists currently entering clinical trials for treatment of hematological tumors
From: The landscape overview of CD47-based immunotherapy for hematological malignancies
Drug Name | Other Name | Companies | Target-based Actions | Drug Classification | Indications | US Highest Phase | Chinese Highest Phase | NCT | CTR |
|---|---|---|---|---|---|---|---|---|---|
AO-176 | AO-104 | Arch Oncology | CD47 antagonist | anti-CD47 monoclonal antibody | Multiple myeloma | Phase II | / | NCT04445701 | / |
CC-90002 | INBRX-103 | Celgene Corp | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase I | / | NCT02367196 | / |
Myelodysplastic syndrome | Phase I | / | NCT02367196 | / | |||||
GenSci-059 | GenSci-059 | GeneScience Pharmaceuticals Co Ltd | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase I | / | NCT05263271 | / |
Myelodysplastic syndrome | Phase I | Â | NCT05263271 | / | |||||
Lemzoparlimab | TJ011133; TJC4 | I-Mab Bio-Tech (Tianjin) Co., Ltd | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase II | Phase II | NCT04202003, NCT04912063 | CTR20210555, CTR20192522 |
Myelodysplastic syndrome | Phase II | Phase III | NCT04202003, NCT04912063 | CTR20210555, CTR20192522, CTR20230090 | |||||
Multiple Myeloma | Phase I | / | NCT04895410 | / | |||||
Letaplimab | IBI-188 | Innovent Biologics Inc | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase II | Phase II | NCT04485052 | CTR20200938 |
Myelodysplastic syndrome | Phase I | Phase III | NCT04511975, NCT04485065 | CTR20201039 | |||||
Ligufalimab | AK117 | Akeso Biopharma Inc | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase II | Phase II | NCT04980885 | CTR20211305 |
Myelodysplastic syndrome | Phase II | Phase II | NCT04900350 | CTR20210825 | |||||
Magrolimab | Hu5F9-G4 | Gilead Sciences | CD47 antagonist | anti-CD47 monoclonal antibody | Myelodysplastic syndrome | Phase III | / | NCT04313881, NCT03527147 | / |
Acute myeloid leukaemia | Phase III | / | NCT05263271, NCT04435691, NCT03248479, NCT03922477, NCT02678338 | / | |||||
Myelodysplastic syndrome | Phase II | / | NCT05263271, NCT03248479, NCT02678338 | / | |||||
ZL-1201 | ZL-1201 | Zai Lab Limited | CD47 antagonist | anti-CD47 monoclonal antibody | hematologic malignancies | Phase I | Phase I | NCT04257617 | CTR20210973 |
IBI-322 | IBI-322 | Innovent Biologics Inc | CD47 antagonist; Programmed cell death ligand 1 inhibitor | bispecific antibody | Hematological neoplasm | Phase I | Phase I | NCT04795128 | CTR20210385 |
Myeloid leukemia | Phase I | Phase I | NCT05148442 | CTR20213120 | |||||
SIRPa-Fc-CD40L | SL-172154 | Shattuck Labs Inc | CD40 ligand receptor agonist; CD47 antagonist | bispecific antibody | Acute myeloid leukaemia | Phase I | Â | NCT05275439 | / |
Myelodysplastic syndrome | Phase I | Â | NCT05275439 | / | |||||
TG-1801 | NI-1701 | TG Therapeutics Inc | B-lymphocyte antigen CD19 modulator; CD47 antagonist; Immunoglobulin Fc receptor agonist | bispecific antibody | Chronic lymphocytic leukemia | Phase I | / | NCT04806035 | / |
XL-114 | AU-341; AU7R-104; AUR-104 | Exelixis Inc | Bcl-10 protein modulator; CD47 antagonist; Caspase recruitment domain protein 11 modulator; Epidermal fatty acid binding protein inhibitor | bispecific antibody | Chronic lymphocytic leukemia | Phase I | / | NCT05144347 | / |
DSP-107 | DSP-107 | KAHR Medical Ltd | CD47 antagonist; CDw137 agonist | SIRPα/Fc fusion protein antibody | Acute myeloid leukaemia | Phase I | / | NCT04937166 | / |
Myelodysplastic syndrome | Phase I | Â | NCT04937166 | / | |||||
Chronic myelomonocytic leukemia | Phase I | / | NCT04937166 | / | |||||
Evorpacept | ALX-148 | ALX Oncology | SIRPα-Fc fusion protein,SIRPα/CD47 blocker | SIRPα/Fc fusion protein antibody | Acute myeloid leukaemia | Phase II | / | NCT04755244 | / |
Myelodysplastic syndrome | Phase II | / | NCT04417517 | / | |||||
IMM-01 | IMM-01 | ImmuneOnco Biopharm Co Ltd | CD47 antagonist | SIRPα/Fc fusion protein antibody | Acute myeloid leukaemia | Phase II | Phase II | NCT05140811 | CTR20212227, CTR20212519 |
Myelodysplastic syndrome | Phase II | Phase II | NCT05140811 | CTR20212227, CTR20212519 | |||||
Multiple myeloma | / | Phase II | / | CTR20212227 | |||||
TTI-621 | TTI-621 | Trillium Therapeutics Inc | CD47 antagonist; Immunoglobulin gamma Fc receptor agonist | SIRPα/Fc fusion protein antibody | Multiple myeloma | Phase I |  | NCT05139225 | / |
Hematological neoplasm | Phase II | / | NCT02663518 | / | |||||
TTI-622 | TTI-622 | Trillium Therapeutics Inc | CD47 antagonist; Immunoglobulin gamma Fc receptor agonist | SIRPα/Fc fusion protein antibody | Acute myelogenous leukemia | Phase I | / | NCT03530683 | / |
Multiple myeloma | Phase I | / | NCT03530683, NCT05139225 | / | |||||
Multiple myeloma | Phase I | / | NCT03530683 | / |